RxDoctor Payments Data

Joseph Surmitis, MD

Cardiovascular Disease · Massillon, OHNPI 1508865213

Payments from drug & device makers

$3,361in general payments, 2019–2025

Across 164 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Johnson & Johnson$672
  • Novartis$593
  • E.r. Squibb & Sons, L.L.C.$168
  • Merck$158
  • AstraZeneca$119
  • plus $180 from 5 others

What the payments were for

  • Food & beverage$3,34399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,361 in reported general payments places this provider in the 60th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$36,182
Medicare patients
346
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban172$150,772
EliquisApixaban149$118,336
Repatha SureclickEvolocumab89$87,668
EntrestoSacubitril/Valsartan63$71,417
FarxigaDapagliflozin Propanediol23$25,962
BrilintaTicagrelor23$20,946
Repatha SyringeEvolocumab12$17,148
Praluent PenAlirocumab12$9,045
Colchicine135$7,959
Ezetimibe237$7,057
EdarbyclorAzilsartan Med/Chlorthalidone22$5,591
Ranolazine ErRanolazine62$4,343
Metoprolol Succinate294$3,909
BystolicNebivolol Hcl12$3,610
Atorvastatin Calcium311$2,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$672$150,772172 claims
NovartisEntresto$593$71,41763 claims
AstraZenecaFarxiga, Brilinta$119$46,90746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Massillon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →